About Paraneoplastic antigen-like protein 8A
Paraneoplastic antigen-like protein 8A (PNMA8A) is a protein
from Homo sapiens identified by UniProt accession
Q86V59, 439 residues long.
MolForge cross-references it against 0 known binders and
31 disease associations.
Target properties
| Protein name | Paraneoplastic antigen-like protein 8A |
| UniProt accession | Q86V59 |
| Gene | PNMA8A |
| Organism | Homo sapiens |
| Length | 439 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (31)
Diseases linked to this target (Open Targets).
- body height · score 0.22
- C-reactive protein measurement · score 0.03
- chronotype measurement · score 0.03
- Stroke · score 0.02
- ovarian carcinoma · score 0.01
- Ataxia-telangiectasia · score 0.01
- colorectal cancer · score 0.01
- cystic fibrosis · score 0.01
- type 1 diabetes mellitus · score 0.01
- Adams-Oliver syndrome · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86V59-F1 | alphafold | PREDICTED | 59.67 | — |
Amino-acid sequence (439 residues)
MSKTMAMNLL EDWCRGMEVD IHRSLLVTGI PEDCGQAEIE ETLNGVLSPL GPYRVLNKIF VREENVKAAL IEVGEGVNLS TIPREFPGRG GVWRVVCRDP TQDAEFLKNL NEFLDAEGRT WEDVVRLLQL NHPTLSQNQH QPPENWAEAL GVLLGAVVQI IFCMDAEIRS REEARAQEAA EFEEMAAWAL AAGRKVKKEP GLAAEVGSAL KAETPNNWNA TEDQHEPTKP LVRRAGAKSR SRRKKQKKNS RQEAVPWKKP KGINSNSTAN LEDPEVGDAE SMAISEPIKG SRKPCVNKEE LALKKPMAKC AWKGPREPPQ DARAEAESPG GASESDQDGG HESPPKKKAV AWVSAKNPAP MRKKKKVSLG PVSYVLVDSE DGRKKPVMPK KGPGSRREAS DQKAPRGQQP AEATASTSRG PKAKPEGSPR RATNESRKV
Explore Paraneoplastic antigen-like protein 8A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets